Partnering Opportunities

Press & News

2021-03-09

San Diego, U.S., Shanghai, China, and Solna, Sweden, March 9, 2021. Affibody AB (“Affibody”)...[read more]

Partnering Opportunities

Affibodys partnering strategy is to engage in partnerships centered around:

Target-by-target development of novel biotherapeutics (discovery collaborations), or
Out-licensing of Albumod™ technology

For opportunities for collaborative, partnership or licensing agreements, please contact bd@affibody.com.

Affibodys latest Press releases

2021-03-09

Affibody and Inmagene announce IND Clearance for izokibep (ABY-035) for the treatment of Non-infectious Non-anterior Uveitis

San Diego, U.S., Shanghai, China, and Solna, Sweden, March 9, 2021. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today...[read more]

Press & News

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

About Affibody

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information